BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Eccogene Enrols First Patient In Phase 2a MOSAIC Trial For MASH Therapies

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammato...

December 18, 2025 | News

GenSci, RTW And Yarrow Forge US Focused Biotech Partnership To Advance First In Class Thyroid Autoimmune Therapy

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology di...

December 17, 2025 | News

Peijia Medical Secures China Regulatory Approval For TaurusTrio Transcatheter Aortic Valve System

Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, a...

December 16, 2025 | News

Everest Medicines Enters Dual Strategic Agreements with Hasten to Drive Accretive Growth

- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveragi...

December 15, 2025 | News

Insilico Medicine Partners with TaiGen to Accelerate AI-Driven Anemia Therapy in Greater China

Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM48...

December 15, 2025 | News

Zealand Pharma And OTR Therapeutics Forge Strategic Collaboration To Advance Next Generation Metabolic Therapies

Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and...

December 12, 2025 | News

Formation Bio Acquires Global Rights To CNS Penetrant TYK2 Inhibitor LNK01006

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio announced Formation Bio's acquisition of wor...

December 11, 2025 | News

D3 Bio Secures One Hundred 8M$ In Series B Funding To Advance Global Late Stage Oncology Trials

D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completio...

December 11, 2025 | News

Innovent Doses First Participant in Phase One Trial of Novel IL One RAP Antibody for Gout

Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ...

December 11, 2025 | News

Fosun Pharma And Pfizer Enter Global GLP One Receptor Agonist Licensing Deal For YP05002

Fosun Pharma announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Devel...

December 10, 2025 | News

Innovent Biologics Seven Innovative Therapies Included in China’s 2025 National Reimbursement Drug List

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high qual...

December 08, 2025 | News

Biocytogen Announces FDA IND Clearance for IDE034 Bispecific B7H3 PTK7 ADC Licensed to IDEAYA Biosciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision o...

December 08, 2025 | News

Kelun Biotech And Crescent Biopharma Forge Global Partnership To Advance Next Generation Oncology Therapies

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets an...

December 05, 2025 | News

Antengene Secures Expanded Approvals For Xpovio In Hong Kong Across Multiple Myeloma And DLBCL

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...

December 04, 2025 | News

Stay Connected